EZZ Life Science Holdings Ltd. AI Stock Analysis
Want to see AU:EZZ full AI Analyst Report?
EZZ Life Science Holdings Ltd. (EZZ) AI Stock Analysis
EZZ Life Science Holdings Ltd.
(ASX:EZZ)
The score is held down primarily by the FY2026 operational setback and cash burn (losses, margin compression, and negative operating/free cash flow), alongside clearly bearish technical trends (price below all major moving averages and negative MACD). The strong low-debt balance sheet provides resilience, and the high dividend yield supports the valuation component, but sustainability risk remains given the latest loss and negative cash flow.
EZZ Life Science Holdings Ltd. (EZZ) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 13.88M
- Dividend Yield
- 13.53%
- Average Volume (3M)
- 18.87K
- Price to Earnings (P/E)
- -2.6
- Beta (1Y)
- 1.31
- Revenue Growth
- -30.79%
- EPS Growth
- -177.68%
- Country
- Australia
- Employees
- 11
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
EZZ Life Science Holdings Ltd. Business Overview & Revenue Model
Company Description
EZZ Life Science Holdings Limited, an Australian company, specializes in offering a range of skincare and consumer health products, with its market presence extending across Australia, New Zealand, Mainland China, and other international territories....
EZZ Life Science Holdings Ltd. Financial Statement Overview
Summary
Financials are mixed but currently pressured: FY2026 saw a sharp revenue decline (-24.6% YoY), a shift to a net loss (net margin -11.5%), negative operating profit, and negative operating/free cash flow. Offsetting this, the balance sheet is strong with very low leverage (debt-to-equity ~0.02) and a still-healthy gross margin level (~55.7%), but the latest downturn materially weakens the near-term profile.
Income Statement
44NeutralBalance Sheet
78PositiveCash Flow
34Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 46.28M | 46.28M | 66.87M | 66.44M | 37.14M | 15.02M |
| Gross Profit | 25.77M | 25.77M | 49.72M | 50.95M | 27.20M | 7.51M |
| EBITDA | -6.12M | -6.12M | 11.10M | 10.38M | 5.09M | 1.90M |
| Net Income | -5.32M | -5.32M | 6.73M | 6.96M | 3.63M | 1.31M |
Balance Sheet | ||||||
| Total Assets | 27.64M | 27.64M | 33.96M | 25.55M | 17.64M | 14.27M |
| Cash, Cash Equivalents and Short-Term Investments | 9.72M | 9.72M | 20.85M | 19.02M | 13.83M | 10.46M |
| Total Debt | 478.59K | 478.59K | 304.49K | 123.86K | 478.59K | 104.57K |
| Total Liabilities | 3.15M | 3.15M | 5.87M | 4.23M | 3.06M | 2.88M |
| Stockholders Equity | 24.49M | 24.49M | 28.09M | 21.32M | 14.58M | 11.39M |
Cash Flow | ||||||
| Free Cash Flow | -8.79M | -8.79M | 4.09M | 5.73M | 3.91M | 1.89M |
| Operating Cash Flow | -8.76M | -8.76M | 4.35M | 6.14M | 4.01M | 1.90M |
| Investing Cash Flow | -652.32K | -652.32K | -546.93K | -441.17K | -101.78K | -13.18K |
| Financing Cash Flow | -1.26M | -1.26M | -2.17M | -582.45K | -761.72K | -277.36K |
EZZ Life Science Holdings Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:EZZ, the sentiment is Negative. The current price of 0.29 is below the 20-day moving average (MA) of 0.31, below the 50-day MA of 0.36, and below the 200-day MA of 0.66, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 36.92 is Neutral, neither overbought nor oversold. The STOCH value of 55.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:EZZ.
EZZ Life Science Holdings Ltd. Peers Comparison
Overall Rating
AU:BIO63Neutral
AU:ZLD52Neutral- AU:EZZ49Neutral
AU:IMC45Neutral
AU:ANR44Neutral
AU:BOT38Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:BIO | 63Neutral | AUD 85.62M | 23.60 | 46.74% | ― | 29.68% | 1520.00% |
| AU:ZLD | 52Neutral | AUD 5.95M | -1.56 | 80.84% | ― | ― | ― |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:EZZ | 49Neutral | AUD 13.88M | -2.61 | -20.36% | 13.53% | -30.79% | -177.68% |
| AU:IMC | 45Neutral | AUD 10.98M | -2.87 | -31.88% | ― | 5.85% | 45.13% |
| AU:ANR | 44Neutral | AUD 2.53M | -2.35 | -101.34% | ― | ― | 64.58% |
| AU:BOT | 38Underperform | AUD 24.86M | -0.31 | -118.74% | ― | 499.47% | 31.20% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:EZZ | EZZ Life Science Holdings Ltd. | 0.29 | -2.12 | -87.80% | |
| AU:ZLD | Zelira Therapeutics Ltd. | 0.50 | 0.16 | 47.06% | |
| AU:IMC | Immuron Limited | 0.04 | -0.03 | -42.19% | |
| AU:ANR | Anatara Lifesciences Ltd | 0.01 | 0.00 | 0.00% | |
| AU:BOT | Botanix Pharmaceuticals Limited | 0.01 | -0.12 | -92.31% | |
| AU:BIO | Biome Australia Ltd | 0.38 | -0.06 | -13.64% |
EZZ Life Science Holdings Ltd. Corporate Events
EZZ Life Science Cushions China Slowdown With Cash Discipline and Skincare Growth
EZZ Life Science reported Q1 FY27 customer receipts of $7.15 million, a 37.67% decline driven by weaker sales on Chinese e-commerce platforms, but significantly improved cash discipline reduced net operating cash outflow to $0.35 million and left the...
EZZ Life Science Sets November AGM, Moves to Digital-First Shareholder Communications
EZZ Life Science Holdings Ltd. has called its Annual General Meeting for 1:00 p.m. AEDT on Friday, 27 November 2026, at its Lidcombe, NSW premises, inviting shareholders to participate in person or via proxy. The company is shifting fully to electron...
EZZ Life Science Sets 2026 AGM to Vote on Board and Capital Mandate
EZZ Life Science Holdings Ltd. has called its annual general meeting for 27 November 2026 in Lidcombe, New South Wales, inviting shareholders to review the financial statements for the year ended 30 June 2026 and the associated directors’ and auditor...
EZZ Life Science Director Christine Chen Reduces Direct Shareholding
EZZ Life Science Holdings Limited has reported a change in the shareholding of director Christine Chen, who disposed of 30,900 ordinary shares in on-market trades conducted between 7 and 8 September 2026. Following these transactions, Chen’s direct h...
EZZ Life Science Outlines 2026 Corporate Governance and Diversity Framework
EZZ Life Science Holdings has released its corporate governance statement for the year ended 30 June 2026, confirming broad adherence to the ASX Corporate Governance Council’s 4th edition principles and recommendations. The board has formalised its o...
EZZ Life Science Releases Annual Report for Year Ended 30 June 2026
EZZ Life Science Holdings Ltd. has released its annual report for the year ended 30 June 2026, providing shareholders and stakeholders with a formal update on its financial and operational performance. The publication of the 2026 annual report marks...
EZZ Life Science Swings to Loss as Revenue Slides and Credit Provisions Rise
EZZ Life Science Holdings Limited reported a steep downturn for the year ended 30 June 2026, with revenues from ordinary activities falling 36.39% to $46.3 million and a swing from a prior-year profit to a net loss after tax of $5.3 million. Underlyi...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 09, 2026